Literature DB >> 2740355

1,25-Dihydroxyvitamin D3 and the regulation of human cancer cell replication.

J A Eisman1, M Koga, R L Sutherland, D H Barkla, P J Tutton.   

Abstract

Several human and animal cancer cell lines have been shown to possess specific high affinity receptors for 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3). The replication of several of these cell types has also been shown to be regulated by this hormone, both in vitro and in vivo. To further understand the mechanisms of these actions, we have examined cancer cells in vitro and in vivo. The in vitro studies extend our previous reports on the treatment of human breast cancer cells (T 47D) with 10(-9) to 10(-6) M 1,25-(OH)2D3, which resulted in a dose- and time-dependent decrease in cell numbers over 6 days. Treatment with 10(-8) M 1,25-(OH)2D3, which reduced cell numbers to approximately one half of those found in control cultures at 6 days, was associated with a doubling of the proportion of cells in the G2 + M phase of the cell cycle and was accompanied by a significant decline in the proportion of G0/G1 cells. At higher concentrations there was a significant decline in S phase cells with accumulation of cells in both G0/G1 and G2 + M phases. The antiestrogen, tamoxifen, at a concentration which caused similar effects on cell number, resulted in proportional decreases in both S and G2 + M phase cells and accumulation of G0/G1 cells. The effects of 1,25-(OH)2D3 on T 47D cell proliferation were associated with time- and concentration-dependent reductions in epidermal growth factor receptor levels to a minimum level of about half that seen in control cultures. The in vivo experiments extend our previous studies, which demonstrated marked inhibition of the growth of human cancer xenografts in immunosuppressed mice by 1,25-(OH)2D3. Xenograft growth was inhibited with 1,25-(OH)2D3 (0.1 microgram ip three times per week) but growth was rapidly restored when the 1,25-(OH)2D3 was withdrawn. Thus, there are clear-cut time- and dose-dependent, yet reversible, effects of 1,25-(OH)2D3 on the replication of human cancer cells in vitro and in vivo, which are possibly mediated through changes in growth factor receptor levels. Further study of these effects may advance understanding of the hormonal control of cellular replication in human cancers.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2740355     DOI: 10.3181/00379727-191-42912

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  8 in total

1.  EB1089, a vitamin D receptor agonist, reduces proliferation and decreases tumor growth rate in a mouse model of hormone-induced mammary cancer.

Authors:  Erin L Milliken; Xiaoxue Zhang; Chris Flask; Jeffrey L Duerk; Paul N MacDonald; Ruth A Keri
Journal:  Cancer Lett       Date:  2005-08-22       Impact factor: 8.679

2.  Vitamin D receptor expression in colorectal cancer.

Authors:  M G Thomas; P A Sylvester; P Newcomb; R J Longman
Journal:  J Clin Pathol       Date:  1999-03       Impact factor: 3.411

3.  Redifferentiation therapy in brain tumors: long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol.

Authors:  P Trouillas; J Honnorat; P Bret; A Jouvet; J P Gerard
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

4.  1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro.

Authors:  C M Hansen; T L Frandsen; N Brünner; L Binderup
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

5.  Vitamin D and melatonin protect the cell's viability and ameliorate the CCl4 induced cytotoxicity in HepG2 and Hep3B hepatoma cell lines.

Authors:  Dilşad Özerkan; Nesrin Özsoy; Erkan Yılmaz
Journal:  Cytotechnology       Date:  2014-07-06       Impact factor: 2.058

Review 6.  Vitamin D status during pregnancy and aspects of offspring health.

Authors:  Anne-Louise Ponsonby; Robyn M Lucas; Sharon Lewis; Jane Halliday
Journal:  Nutrients       Date:  2010-03-23       Impact factor: 5.717

7.  Inhibition of development of N,N'-dimethylhydrazine-induced rat colonic aberrant crypt foci by pre, post and simultaneous treatments with 24R,25-dihydroxyvitamin D3.

Authors:  E I Salim; H Wanibuchi; T Taniyama; Y Yano; K Morimura; S Yamamoto; S Otani; Y Nishizawa; H Morii; S Fukushima
Journal:  Jpn J Cancer Res       Date:  1997-11

8.  1alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells.

Authors:  N Dunlap; G G Schwartz; D Eads; S D Cramer; A B Sherk; V John; C Koumenis
Journal:  Br J Cancer       Date:  2003-08-18       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.